

# Kevin Pethe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7322668/publications.pdf>

Version: 2024-02-01

91  
papers

6,838  
citations

70961

41  
h-index

64668

79  
g-index

92  
all docs

92  
docs citations

92  
times ranked

7561  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. <i>Nature Medicine</i> , 2013, 19, 1157-1160.	15.2	509
2	The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating <i>Mycobacterium tuberculosis</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 11945-11950.	3.3	471
3	The heparin-binding haemagglutinin of <i>M. tuberculosis</i> is required for extrapulmonary dissemination. <i>Nature</i> , 2001, 412, 190-194.	13.7	411
4	Lysosomal killing of <i>Mycobacterium</i> mediated by ubiquitin-derived peptides is enhanced by autophagy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 6031-6036.	3.3	305
5	Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for <i>Mycobacterium tuberculosis</i> to establish and maintain infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 9819-9824.	3.3	299
6	Isolation of <i>Mycobacterium tuberculosis</i> mutants defective in the arrest of phagosome maturation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 13642-13647.	3.3	291
7	Nutrient-starved, non-replicating <i>Mycobacterium tuberculosis</i> requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. <i>Microbiology (United Kingdom)</i> , 2010, 156, 81-87.	0.7	251
8	A chemical genetic screen in <i>Mycobacterium tuberculosis</i> identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. <i>Nature Communications</i> , 2010, 1, 57.	5.8	250
9	para-Aminosalicylic Acid Is a Prodrug Targeting Dihydrofolate Reductase in <i>Mycobacterium tuberculosis</i> . <i>Journal of Biological Chemistry</i> , 2013, 288, 23447-23456.	1.6	158
10	Targeting Bacterial Central Metabolism for Drug Development. <i>Chemistry and Biology</i> , 2014, 21, 1423-1432.	6.2	153
11	Lead Optimization of a Novel Series of Imidazo[1,2- <i>a</i> ]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5293-5305.	2.9	153
12	Biosynthesis and Recycling of Nicotinamide Cofactors in <i>Mycobacterium tuberculosis</i> . <i>Journal of Biological Chemistry</i> , 2008, 283, 19329-19341.	1.6	152
13	The Natural Product Cyclomarin Kills <i>Mycobacterium Tuberculosis</i> by Targeting the ClpC1 Subunit of the Caseinolytic Protease. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 5889-5891.	7.2	149
14	The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD. <i>Respirology</i> , 2017, 22, 634-650.	1.3	143
15	Exploiting the synthetic lethality between terminal respiratory oxidases to kill <i>Mycobacterium tuberculosis</i> and clear host infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7426-7431.	3.3	141
16	Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis. <i>Science Translational Medicine</i> , 2013, 5, 214ra168.	5.8	134
17	Methylation-dependent T cell immunity to <i>Mycobacterium tuberculosis</i> heparin-binding hemagglutinin. <i>Nature Medicine</i> , 2004, 10, 935-941.	15.2	131
18	A High-Throughput Screen To Identify Inhibitors of ATP Homeostasis in Non-replicating <i>Mycobacterium tuberculosis</i> . <i>ACS Chemical Biology</i> , 2012, 7, 1190-1197.	1.6	123

#	ARTICLE	IF	CITATIONS
19	Triacylglycerol Utilization Is Required for Regrowth of In Vitro Hypoxic Nonreplicating <i>Mycobacterium bovis</i> Bacillus Calmette-Guerin. <i>Journal of Bacteriology</i> , 2009, 191, 5037-5043.	1.0	119
20	Characterization of the Heparin-binding Site of the Mycobacterial Heparin-binding Hemagglutinin Adhesin. <i>Journal of Biological Chemistry</i> , 2000, 275, 14273-14280.	1.6	110
21	Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyllysines that confer resistance to proteolysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10759-10764.	3.3	110
22	Differential T and B Cell Responses against Mycobacterium tuberculosis Heparin-binding Hemagglutinin Adhesin in Infected Healthy Individuals and Patients with Tuberculosis. <i>Journal of Infectious Diseases</i> , 2002, 185, 513-520.	1.9	109
23	Mycobacterium tuberculosis with Disruption in Genes Encoding the Phosphate Binding Proteins PstS1 and PstS2 Is Deficient in Phosphate Uptake and Demonstrates Reduced In Vivo Virulence. <i>Infection and Immunity</i> , 2005, 73, 1898-1902.	1.0	105
24	Nitrate Respiration Protects Hypoxic Mycobacterium tuberculosis Against Acid- and Reactive Nitrogen Species Stresses. <i>PLoS ONE</i> , 2010, 5, e13356.	1.1	91
25	Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions. <i>Microbiology Spectrum</i> , 2017, 5, .	1.2	89
26	Microbiomes in respiratory health and disease: An Asia-Pacific perspective. <i>Respirology</i> , 2017, 22, 240-250.	1.3	88
27	Enantiomeric glycosylated cationic block co-beta-peptides eradicate Staphylococcus aureus biofilms and antibiotic-tolerant persisters. <i>Nature Communications</i> , 2019, 10, 4792.	5.8	88
28	Transient Requirement of the PrrA-PrrB Two-Component System for Early Intracellular Multiplication of Mycobacterium tuberculosis. <i>Infection and Immunity</i> , 2002, 70, 2256-2263.	1.0	87
29	Sensitive profiling of chemically diverse bioactive lipids. <i>Journal of Lipid Research</i> , 2007, 48, 1976-1984.	2.0	82
30	Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	79
31	Enhanced bacterial virulence through exploitation of host glycosaminoglycans. <i>Molecular Microbiology</i> , 2002, 43, 1379-1386.	1.2	75
32	Polymers as advanced antibacterial and antibiofilm agents for direct and combination therapies. <i>Chemical Science</i> , 2022, 13, 345-364.	3.7	74
33	Nanoparticles of Short Cationic Peptidopolysaccharide Self-Assembled by Hydrogen Bonding with Antibacterial Effect against Multidrug-Resistant Bacteria. <i>ACS Applied Materials &amp; Interfaces</i> , 2017, 9, 38288-38303.	4.0	67
34	Urease Activity Represents an Alternative Pathway for Mycobacterium tuberculosis Nitrogen Metabolism. <i>Infection and Immunity</i> , 2012, 80, 2771-2779.	1.0	65
35	Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer. <i>Nature Communications</i> , 2018, 9, 5370.	5.8	64
36	A Glycosylated Cationic Block Poly( $\beta$ -peptide) Reverses Intrinsic Antibiotic Resistance in All ESKAPE Gram-Negative Bacteria. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 6819-6826.	7.2	63

#	ARTICLE	IF	CITATIONS
37	Antimicrobial Effect of a Novel Chitosan Derivative and Its Synergistic Effect with Antibiotics. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 3237-3245.	4.0	57
38	<i>Mycobacterium smegmatis</i> laminin-binding glycoprotein shares epitopes with <i>Mycobacterium tuberculosis</i> heparin-binding haemagglutinin. <i>Molecular Microbiology</i> , 2001, 39, 89-99.	1.2	56
39	Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of <i>Mycobacterium tuberculosis</i> . <i>MBio</i> , 2018, 9, .	1.8	52
40	Role of ADP-Ribosyltransferase Activity of Pertussis Toxin in Toxin-Adhesin Redundancy with Filamentous Hemagglutinin during <i>Bordetella pertussis</i> Infection. <i>Infection and Immunity</i> , 2001, 69, 6038-6043.	1.0	48
41	Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant <i>Mycobacterium tuberculosis</i> . <i>EMBO Molecular Medicine</i> , 2021, 13, e13207.	3.3	47
42	Characterization of Phosphofructokinase Activity in <i>Mycobacterium tuberculosis</i> Reveals That a Functional Glycolytic Carbon Flow Is Necessary to Limit the Accumulation of Toxic Metabolic Intermediates under Hypoxia. <i>PLoS ONE</i> , 2013, 8, e56037.	1.1	46
43	Inhibitors of energy metabolism interfere with antibiotic-induced death in mycobacteria. <i>Journal of Biological Chemistry</i> , 2019, 294, 1936-1943.	1.6	46
44	Discovery of Tetrahydropyrazolopyrimidine Carboxamide Derivatives As Potent and Orally Active Antitubercular Agents. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 451-455.	1.3	43
45	Precisely Structured Nitric-Oxide-Releasing Copolymer Brush Defeats Broad-Spectrum Catheter-Associated Biofilm Infections <i>In Vivo</i> . <i>ACS Central Science</i> , 2020, 6, 2031-2045.	5.3	41
46	New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in <i>Mycobacterium tuberculosis</i> . <i>PLoS Pathogens</i> , 2020, 16, e1008270.	2.1	38
47	Isolation and Characterization of a Hybrid Respiratory Supercomplex Consisting of <i>Mycobacterium tuberculosis</i> Cytochrome bcc and <i>Mycobacterium smegmatis</i> Cytochrome aa3. <i>Journal of Biological Chemistry</i> , 2015, 290, 14350-14360.	1.6	36
48	Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in <i>Mycobacterium tuberculosis</i> . <i>Nature Communications</i> , 2020, 11, 6092.	5.8	34
49	High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 693-697.	1.4	33
50	Eighty-Kilodalton N-Terminal Moiety of <i>Bordetella pertussis</i> Filamentous Hemagglutinin: Adherence, Immunogenicity, and Protective Role. <i>Infection and Immunity</i> , 2002, 70, 4142-4147.	1.0	29
51	Targeting the cytochrome oxidases for drug development in mycobacteria. <i>Progress in Biophysics and Molecular Biology</i> , 2020, 152, 45-54.	1.4	29
52	Oxidative Phosphorylation—an Update on a New, Essential Target Space for Drug Discovery in <i>Mycobacterium tuberculosis</i> . <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2339.	1.3	29
53	Discovery of a Novel <i>Mycobacterial</i> ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 13295-13304.	7.2	28
54	A rheostat mechanism governs the bifurcation of carbon flux in mycobacteria. <i>Nature Communications</i> , 2016, 7, 12527.	5.8	27

#	ARTICLE	IF	CITATIONS
55	Carbon metabolism modulates the efficacy of drugs targeting the cytochrome bc1:aa3 in <i>Mycobacterium tuberculosis</i> . <i>Scientific Reports</i> , 2019, 9, 8608.	1.6	26
56	Therapeutic potential of promiscuous targets in <i>Mycobacterium tuberculosis</i> . <i>Current Opinion in Pharmacology</i> , 2018, 42, 22-26.	1.7	25
57	Mixed-charge pseudo-zwitterionic copolymer brush as broad spectrum antibiofilm coating. <i>Biomaterials</i> , 2021, 273, 120794.	5.7	24
58	EthA/R-Independent Killing of <i>Mycobacterium tuberculosis</i> by Ethionamide. <i>Frontiers in Microbiology</i> , 2017, 8, 710.	1.5	23
59	Target Engagement and Binding Mode of an Antituberculosis Drug to Its Bacterial Target Deciphered in Whole Living Cells by NMR. <i>Biochemistry</i> , 2019, 58, 526-533.	1.2	19
60	<i>M. tuberculosis</i> Rv2252 encodes a diacylglycerol kinase involved in the biosynthesis of phosphatidylinositol mannosides (PIMs). <i>Molecular Microbiology</i> , 2006, 60, 1152-1163.	1.2	17
61	Active pulmonary targeting against tuberculosis (TB) via triple-encapsulation of Q203, bedaquiline and superparamagnetic iron oxides (SPIOs) in nanoparticle aggregates. <i>Drug Delivery</i> , 2019, 26, 1039-1048.	2.5	17
62	Structure guided generation of thieno[3,2- <i>d</i> ]pyrimidin-4-amine <i>Mycobacterium tuberculosis</i> <i>bd</i> oxidase inhibitors. <i>RSC Medicinal Chemistry</i> , 2021, 12, 73-77.	1.7	17
63	An <i>ethA-ethR</i> -Deficient <i>Mycobacterium bovis</i> BCG Mutant Displays Increased Adherence to Mammalian Cells and Greater Persistence <i>In Vivo</i> , Which Correlate with Altered Mycolic Acid Composition. <i>Infection and Immunity</i> , 2014, 82, 1850-1859.	1.0	16
64	Toward a Single-Dose Cure for Buruli Ulcer. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	16
65	Contribution of high-resolution imaging technologies to the development of anti-infective drugs. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016, 89, 755-760.	1.1	15
66	Features and Functional Importance of Key Residues of the <i>Mycobacterium tuberculosis</i> Cytochrome <i>bd</i> Oxidase. <i>ACS Infectious Diseases</i> , 2020, 6, 1697-1707.	1.8	11
67	A Glycosylated Cationic Block Poly( $\alpha$ -peptide) Reverses Intrinsic Antibiotic Resistance in All ESKAPE Gram-Negative Bacteria. <i>Angewandte Chemie</i> , 2020, 132, 6886-6893.	1.6	11
68	Telacebec: an investigational antibacterial for the treatment of tuberculosis (TB). <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 139-144.	1.9	11
69	Recombinase-based reporter system and antisense technology to study gene expression and essentiality in hypoxic nonreplicating mycobacteria. <i>FEMS Microbiology Letters</i> , 2008, 284, 68-75.	0.7	10
70	Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with <i>Mycobacterium ulcerans</i> after only 16 doses. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0007857.	1.3	10
71	Antituberculosis Activity of the Antimalaria Cytochrome <i>bcc</i> Oxidase Inhibitor SCR0911. <i>ACS Infectious Diseases</i> , 2020, 6, 725-737.	1.8	10
72	Naturally-Occurring Polymorphisms in <i>QcrB</i> Are Responsible for Resistance to Telacebec in <i>Mycobacterium abscessus</i> . <i>ACS Infectious Diseases</i> , 2019, 5, 2055-2060.	1.8	9

#	ARTICLE	IF	CITATIONS
73	Next-generation antimicrobials: from chemical biology to first-in-class drugs. Archives of Pharmacal Research, 2015, 38, 1702-1717.	2.7	8
74	Sensitivity of <i>Mycobacterium leprae</i> to Telacebec. Emerging Infectious Diseases, 2022, 28, 749-751.	2.0	8
75	Interaction of human Tamm-Horsfall glycoprotein with Bordetella pertussis toxin. Microbiology (United Kingdom), 2002, 148, 1193-1201.	0.7	7
76	HflX is a GTPase that controls hypoxia-induced replication arrest in slow-growing mycobacteria. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	5
77	Role of the CD137 ligand (CD137L) signaling pathway during Mycobacterium tuberculosis infection. Immunobiology, 2014, 219, 78-86.	0.8	4
78	Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions. , 0, , 295-316.		4
79	Discovery of a Novel Mycobacterial ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines. Angewandte Chemie, 2020, 132, 13397-13406.	1.6	4
80	Syntheses and Structure-Activity Relationships of N-Phenethyl-Quinazolin-4-yl-Amines as Potent Inhibitors of Cytochrome bd Oxidase in Mycobacterium tuberculosis. Applied Sciences (Switzerland), 2021, 11, 9092.	1.3	3
81	The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0096421.	1.4	0
82	Determination of Bioenergetic Parameters in Mycobacterium ulcerans. Methods in Molecular Biology, 2022, 2387, 219-230.	0.4	0
83	Turbidity-Based MIC Assay and Characterization of Spontaneous Drug Resistant Mutants in Mycobacterium ulcerans. Methods in Molecular Biology, 2022, 2387, 209-217.	0.4	0
84	Tuberculose, la porte vers la dissémination extra-pulmonaire. Medecine/Sciences, 2001, 17, 1220-1221.	0.0	0
85	Sensitivity of <i>Mycobacterium leprae</i> to Telacebec. Emerging Infectious Diseases, 2022, 28, 749-751.	2.0	0
86	Title is missing!. , 2020, 14, e0007857.		0
87	Title is missing!. , 2020, 14, e0007857.		0
88	Title is missing!. , 2020, 14, e0007857.		0
89	Title is missing!. , 2020, 14, e0007857.		0
90	Title is missing!. , 2020, 14, e0007857.		0

#	ARTICLE	IF	CITATIONS
91	Title is missing!. , 2020, 14, e0007857.		0